A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Dec 3, 2019

Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics

- Complementary capabilities and resources of the two organizations create an industry-leading gene therapy company

TOKYO and SAN FRANCISCO, December 2, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Audentes Therapeutics, Inc. (NASDAQ: BOLD, Chairman and...

Read more about Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics
Dec 3, 2019

ACQUISITION OF AUDENTES Establishing a leading position in gene therapy

Read more about ACQUISITION OF AUDENTES Establishing a leading position in gene therapy
Dec 3, 2019

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer

- Companies to Initiate Phase 3 Trial to Support Global Registrations -

BOTHELL, Wash., and TOKYO, December 2, 2019 – Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced...

Read more about Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer
Dec 3, 2019

Astellas Presents New Data on XOSPATA® (gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual Meeting

Emerging mutations in patients with treatment resistance, from Phase 3 ADMIRAL study, will be focus of oral presentation

TOKYO, Dec. 3, 2019 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the presentation of new data in acute myeloid leukemia (AML) at...

Read more about Astellas Presents New Data on XOSPATA® (gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual Meeting
Dec 2, 2019

Astellas Announces Status of Acquisition of Own Shares

Read more about Astellas Announces Status of Acquisition of Own Shares
Nov 26, 2019

Astellas Announces the Approval of XTANDI® (enzalutamide) by the China National Medical Products Administration (NMPA) Approval based on Asian PREVAIL study of men with metastatic castration-resistant prostate cancer

TOKYO, November 26, 2019 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the China National Medical Products Administration...

Read more about Astellas Announces the Approval of XTANDI® (enzalutamide) by the China National Medical Products Administration (NMPA) Approval based on Asian PREVAIL study of men with metastatic castration-resistant prostate cancer
Nov 21, 2019

Astellas and Welldoc Enter into Strategic Alliance for Digital Therapeutics - Develop and commercialize digital health solutions globally for multiple therapeutic areas, including in Japan for diabetes patients -

TOKYO and Columbia, Maryland, November 20, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and Welldoc, Inc. (President, CEO: Kevin McRaith,...

Read more about Astellas and Welldoc Enter into Strategic Alliance for Digital Therapeutics - Develop and commercialize digital health solutions globally for multiple therapeutic areas, including in Japan for diabetes patients -
Nov 20, 2019

Launch of Evrenzo® (roxadustat) Tablets in Japan for the Treatment of Renal Anemia in Patients on Dialysis - First-in-Class Orally Administered HIF-PH Inhibitor -

TOKYO, November 20, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced launch of Evrenzo® Tablet 20mg, 50mg and 100mg (generic...

Read more about Launch of Evrenzo® (roxadustat) Tablets in Japan for the Treatment of Renal Anemia in Patients on Dialysis - First-in-Class Orally Administered HIF-PH Inhibitor -
Oct 31, 2019

Astellas Announces Acquisition of Own Shares and Cancellation of Treasury Stock

(Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act and cancellation of treasury stock pursuant to the provisions of Article 178 of the Companies Act)

Tokyo, October 31, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.) today announced that at the meeting of the Board of Directors held today, a resolution was...

Read more about Astellas Announces Acquisition of Own Shares and Cancellation of Treasury Stock
Oct 31, 2019

PANDION AND ASTELLAS ANNOUNCE COLLABORATION TO DELIVER PANCREAS-TARGETED IMMUNOMODULATORS

Exclusive Collaboration Utilizes Pandion’s Platform to Discover Novel Tissue-Specific Immunomodulators for Type 1 Diabetes and Other Autoimmune Diseases of the Pancreas

Cambridge, MA, and Tokyo, October 31, 2019 - Pandion Therapeutics, Inc. (“Pandion”), and Astellas Pharma Inc. (TSE: 4503, "Astellas") announced today the signing of a License and Collaboration...

Read more about PANDION AND ASTELLAS ANNOUNCE COLLABORATION TO DELIVER PANCREAS-TARGETED IMMUNOMODULATORS

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts